TCAF2

Across TCGA pan-cancer cohorts, TCAF2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TCAF2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TCAF2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TCAF2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, CCRCC, and HNSC are the cancer types where TCAF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.525	0.904	.012	14	view →
CCRCC	OS	Quartile	All	0.665	0.952	.004	12	view →
HNSC	DFS	Tertile	III,IV	0.926	0.688	.006	10	view →
GBM	DFS	Median	All	0.633	0.786	.018	3	view →
PDAC	OS	Median	All	0.414	1.000	.040	2	view →
LSCC	DFS	Median	II,III,IV	0.444	0.883	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TCAF2–LUAD (OS)

Open the LUAD breakdown →